NASDAQ:RARX - Ra Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$9.55 +0.37 (+4.03 %)
(As of 06/19/2018 04:00 PM ET)
Previous Close$9.18
Today's Range$9.05 - $9.63
52-Week Range$4.78 - $23.59
Volume347,300 shs
Average Volume226,566 shs
Market Capitalization$293.16 million
P/E Ratio-3.96
Dividend YieldN/A
Beta2.22
Ra Pharmaceuticals logoRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Debt-to-Equity RatioN/A
Current Ratio15.37
Quick Ratio15.37

Price-To-Earnings

Trailing P/E Ratio-3.96
Forward P/E Ratio-4.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.93 million
Price / Sales62.55
Cash FlowN/A
Price / CashN/A
Book Value$3.06 per share
Price / Book3.12

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-54,430,000.00
Net MarginsN/A
Return on Equity-66.83%
Return on Assets-60.01%

Miscellaneous

Employees63
Outstanding Shares32,290,000

Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.05. View Ra Pharmaceuticals' Earnings History.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Ra Pharmaceuticals.

What price target have analysts set for RARX?

5 brokers have issued 12-month target prices for Ra Pharmaceuticals' stock. Their forecasts range from $14.00 to $31.00. On average, they expect Ra Pharmaceuticals' share price to reach $22.00 in the next year. View Analyst Ratings for Ra Pharmaceuticals.

Who are some of Ra Pharmaceuticals' key competitors?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas A. Treco, CEO, Pres, Co-Founder & Director (Age 60)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 54)
  • Dr. Simon Read Ph.D., Chief Scientific Officer (Age 47)
  • Dr. Ramin Farzaneh-Far M.D., FACC, Chief Medical Officer (Age 41)
  • Ms. Kerry Black M.S., M.B.A., Exec. Director of Operations

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an initial public offering (IPO) on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Has Ra Pharmaceuticals been receiving favorable news coverage?

Headlines about RARX stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ra Pharmaceuticals earned a coverage optimism score of 0.10 on Accern's scale. They also gave media headlines about the company an impact score of 44.92 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Ra Pharmaceuticals' major shareholders?

Ra Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (17.01%), BlackRock Inc. (3.57%), Millennium Management LLC (2.08%), Foresite Capital Management IV LLC (1.39%), JPMorgan Chase & Co. (1.35%) and Eventide Asset Management LLC (1.20%). Company insiders that own Ra Pharmaceuticals stock include Bioventures Ltd Novartis, Enterprise Associates 13 L New, Harry R Weller, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Institutional Ownership Trends for Ra Pharmaceuticals.

Which major investors are buying Ra Pharmaceuticals stock?

RARX stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Foresite Capital Management IV LLC, Eventide Asset Management LLC, Acuta Capital Partners LLC, Millennium Management LLC, BlackRock Inc., JPMorgan Chase & Co. and Dimensional Fund Advisors LP. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Harry R Weller, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $9.55.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $293.16 million and generates $4.93 million in revenue each year. The company earns $-54,430,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Ra Pharmaceuticals employs 63 workers across the globe.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (RARX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.